{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:46Z","timestamp":1793317606299,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010806","name":"Amgen Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bone.2020.115478","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T02:01:25Z","timestamp":1591840885000},"page":"115478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha M.","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bone.2020.115478_bb0005","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after Denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115478_bb0010","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2020.115478_bb0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of Denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2020.115478_bb0020","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2020.115478_bb0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1530\/EJE-16-1027","article-title":"Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment","volume":"176","author":"Anastasilakis","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2020.115478_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115478_bb0035","doi-asserted-by":"crossref","unstructured":"A.D. Anastasilakis, S.E. Papapoulos, S.A. Polyzos, N.M. Appelman-Dijkstra, P. Makras, Zoledronate for the prevention of bone loss in women discontinuing Denosumab treatment. A prospective 2-year clinical trial, J. Bone Miner. Res. 34(12) (2019) 2220\u20132228.","DOI":"10.1002\/jbmr.3853"},{"issue":"S1","key":"10.1016\/j.bone.2020.115478_bb0040","first-page":"60","article-title":"Treatment with zoledronic acid subsequent to treatment with denosumab","volume":"34","author":"S\u00f8lling","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2020.115478_bb0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping Denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2020.115478_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following Denosumab discontinuation results in partial conservation of bone mass gains","author":"Everts-Graber","year":"2020","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220302581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220302581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:52:05Z","timestamp":1757613125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220302581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":10,"alternative-id":["S8756328220302581"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115478","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115478"}}